Conducted by VSU
, Started on 2021 -
Completed on 2025
Completed
Published
Total Page Views : 29
Total Likes : 13
Like
Plants have been valuable sources of new drugs for the treatment of metabolic disorders, such as
Diabetes mellitus. Its utilization has been accelerating for the past decades coupled with heightened safety in pre-
clinical development and clinical trials which remains challenging for the pharmaceutical industry. The significance
of these plants stems from their phytochemical constituents such as carotenoids, flavonoids, terpenoids, alkaloids,
glycosides which often have anti-diabetic effects (Kooti et al., 2016). Currently available therapies for diabetes
include insulin and various oral antidiabetic agents such as sulfonylureas, biguanides and glinides have a number
of serious adverse effects (Patel et al., 2012). As such, herbal medicines are gaining importance as they are cost-
effective and also display improved therapeutic effects with lesser side effects. (Jacob et al., 2018). In the previous
study of Tulin et al., (2024), five-candidate antidiabetic indigenous plants including Swietenia mahagoni (L.) Jacq.
(‘mahogany’), Basella rubra L. (red ‘alugbati’), Cycas vespertilio A. Lindstr. & K.D. Hill. (‘Pitogo’), Anodendron
oblongifolium Hemsl. (red ‘magsumpay’), and Mimosa pudica L. (makahiya) revealed promising alpha-glucosidase
enzyme inhibition. These encouraging bioactivity underscores the need to further substantiate the findings with
complementary analysis.
This study focused on the five anti-diabetic candidate plant extracts on their toxicity, bioactivity, and
molecular characterization of the lead compounds present in the extracts. Solid-liquid solvent extraction followed
by liquid-liquid solvent partition was employed to obtain plant extracts of varying degree of polarity retaining the
extracts which exhibited bioactivity for subsequent investigation.